Deborah O’Neil PhD FRSE
NovaBiotics is a biotechnology company focused on the development of first-in-class anti-infectives for difficult-to-treat diseases.
It is led by Deborah O’Neill who has trained in immunology at some of the world’s best laboratories – including UCL and UC San Diego. As CEO she’s proven as adept in the world of business as she is in that of biology.
She has helped NovaBiotics raise over £20 million in equity funding since helping it spin out of the Rowett Research Institute. NovaBiotics now counts bases in Aberdeen and North Carolina.
Outside of NovaBiotics, Deborah is editor of the European Biopharmaceutical Review and International Pharmaceutical Technology, and a board member of the Scottish Life Sciences Association. Last year she was named in the top 15 of Europe’s biotechnology female leaders, adding to a mantlepiece that includes the EY award for Entrepreneur of the Year in Healthcare Products and Services 2014.
Reflecting on her career so far, Deborah says never underestimate your potential, “My advice to anyone would be to realise that you will learn and develop more than you ever expected along the journey.”